DaVita (BSP:DVAI34) Change In Receivables : R$888 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is DaVita Change In Receivables?

DaVita's change in receivables for the quarter that ended in Dec. 2023 was R$108 Mil. It means DaVita's Accounts Receivable declined by R$108 Mil from Sep. 2023 to Dec. 2023 .

DaVita's change in receivables for the fiscal year that ended in Dec. 2023 was R$845 Mil. It means DaVita's Accounts Receivable declined by R$845 Mil from Dec. 2022 to Dec. 2023 .

DaVita's Accounts Receivable for the quarter that ended in Dec. 2023 was R$9,735 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. DaVita's Days Sales Outstanding for the three months ended in Dec. 2023 was 57.63.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. DaVita's liquidation value for the three months ended in Dec. 2023 was R$-59,762 Mil.

DaVita Change In Receivables Historical Data

The historical data trend for DaVita's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DaVita Change In Receivables Chart

DaVita Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-316.73

-516.34

-781.17

-778.39

844.53

DaVita Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-296.37	773.19	127.36	-120.53	108.19

DaVita Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$888 Mil.

DaVita (BSP:DVAI34) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

DaVita's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	9735.197	/	15413.531	*	91
=	57.63

2. In Ben Graham's calculation of liquidation value, DaVita's accounts receivable are only considered to be worth 75% of book value:

DaVita's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1919.119	-	69333.287	+	0.75 * 9735.197	+	0.5 * 701.186
=	-59,762

DaVita Change In Receivables Related Terms

Thank you for viewing the detailed overview of DaVita's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

DaVita (BSP:DVAI34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (BSP:DVAI34) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

DVA:USA TRL:Germany

Address

2000 16th Street, Denver, CO, USA, 80202

Website

https://www.davita.com

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

DaVita (BSP:DVAI34) Headlines

No Headlines